Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

Posts in ‘News’

May 4th, 2018 – Aurgalys, Listing Sponsor Euronext, is pleased to announce the listing of Parx Plastics on Euronext Access Paris. Parx Plastics is a Netherlands company specialized in antimicrobial plastics

mai 07, 2018

Paris- Evry, France, May 4th, 2018– Aurgalys, a global provider and Listing Sponsor for life sciences and healthcare companies through corporate finance, business development, and equity research services, announces the successful listing of Parx Plastics NV [ISIN code: NL0012650535; Ticker: MLPRX] on Euronext Access Paris through a private placement.

Parx Plastics N.V. is a Netherlands based company which has developed and patented an innovative technology to make plastics antimicrobial by making use of an essential nutrient. The integration of a body’s own trace element in plastics, results in a defence mechanism against bacteria reducing the number of bacteria on the surface by 99% and higher.

The antimicrobial plastic market size, in terms of value, is projected to reach EURO 13.75 billion by 2020, at a CAGR of 8.7%, between 2015 and 2020. Healthcare is accounting for more than one-third share of the market and is the key application of antimicrobial plastic, followed by packaging and consumer goods.

The technology is derived from biomimicry with the aim to develop a safe and biocompatible antimicrobial solution. By integrating an essential nutrient in existing raw materials a defence mechanism is created protecting the material against bacteria, molds, fungi and biofilm. The technology results in an antimicrobial effect of 99% and higher when tested according to international norm ISO22196 for the measurement of antibacterial activity on plastics.

The biocompatibility and the fact that the technology does not rely on leaching make it a unique solution that can be safely used for food contact application (e.g. food packaging) and for medical applications (e.g. implants).

Parx Plastics shares are being listed on Euronext Access™ Paris stock exchange through a private placement procedure. The issued share capital of Parx Plastics currently comprises of 6,810,582 shares. Based on a price per share of € 3.57 at the time of listing, the company’s market capitalization is € 24.3 million.

April 9th, 2018: Aurgalys initiates coverage of Noxxon Pharma listed on Euronext Growth Paris [ALNOX]

avril 10, 2018

Evry – Genopole & Paris, April 9th, 2018

Aurgalys launches Noxxon Pharma coverage today with analyst reports in English and French. Noxxon Pharma is a company specializing in cancer immunotherapy, which develops several products from its proprietary technology platform, including NOX-A12 and NOX-E36 that specifically address solid tumors such as colorectal cancer, pancreatic cancer and glioblastoma. Our target share price is € 17.95

The reports will be available to institutional investors on the Aurgalys and Noxxon websites, as well as on the financial data providers websites

Coverage initiation in english

Aurgalys initie la couverture de NOXXON Pharma à partir d’aujourd’hui. Noxxon Pharma est une société spécialisée en immunothérapie du cancer, qui développe plusieurs produits issus de sa plateforme technologique propriétaire, dont NOX-A12 et NOX-E36 qui adressent spécifiquement des tumeurs solides dont le cancer colorectal, le cancer du pancréas et le glioblastome. Notre objectif de cours par action est de 17,95€

L’initiation de couverture et les rapports d’analyes seront disponibles en anglais et en français. Ils seront accessibles aux investisseurs professionnels sur les sites Web d’Aurgalys et de Noxxon Pharma ainsi qu’auprès des plateformes financières spécialisées.

Initiation de couverture en français

March 23rd, 2018 – Aurgalys, Listing Sponsor Euronext, is pleased to announce the listing of Media Lab, an Italian company dedicated to dental surgery, within Euronext Access Paris

mars 23, 2018

Paris- Evry, France, March 23rd, 2018– Aurgalys, a global provider and Listing Sponsor for life sciences and healthcare companies through corporate finance, business development, and equity research services, announces the successful listing of the italian company Media Lab [ISIN code: IT0005324105,Ticker: MLLAB] on Euronext Access Paris through a private placement

Media Lab is dedicated to the development and marketing of digital solutions for dental practices. The company has developed two product lines, the first one dedicated to the management of dental practice, named Confident, the second one being dental implant guided surgery, named Implant 3D and GuideDesign. Media Lab products address a growing European market currently valued at about € 450 million by 2024 for dental management software and above € 60 million by 2023 for guided-surgery.

To download the press release in english

Pour télécharger le communiqué de presse en français

Jan. 19th, 2018: Aurgalys Value has decided to publish all its analyst reports in two languages, french and english

janvier 19, 2016

Paris- Evry, France, Jan. 19th, 2018 – Aurgalys Value, a specialist equity research provider for life sciences and healthcare companies, announces today that all analyst reports on listed companies will be published in two languages, french and english

Considering the growing number of Anglophone investors dedicated to the life sciences and health sector, or biotech-medtech, interested in the Euronext market, Aurgalys Value, a specialist in financial analysis for this sector, now offers its analyzes in English-French bilingual format.

Paris- Evry, France, le 19 janvier 2018 – Aurgalys Value, spécialiste de la recherche actions pour les entreprises du secteur des sciences de la vie et de la santé, annonce aujourd’hui que tous les rapports d’analyses sur les sociétés cotées seront publiés en deux langues: français et anglais

Considérant le nombre croissant d’investisseurs anglophone dédiés au secteur des sciences de la vie et de la santé, ou biotech – medtech, s’intéressant au marché Euronext, Aurgalys Value, spécialiste de l’analyse financière pour ce secteur propose dorénavant ses analyses en format bilingue anglais-français.

 

Nov. 25th, 2015: Aurgalys initiates coverage on Sensorion [Euronext: ALSEN]

novembre 25, 2015

Paris- Evry, France, Nov. 25th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on Sensorion.

« Sensorion is a biopharmaceutical company, specializing in the development of drugs for inner ear disorders. Its lead product, SENS-111, is a Phase II-ready drug candidate for the treatment of vertigo and tinnitus. The company announced positive Phase Ib results confirming the safety and tolerability of SENS-111 in healthy volunteers. The company also develops SENS-218 for vestibular lesions. SENS-218 is a molecule from the setron class, a well known family of antiemetic drugs. A pilot study already conducted in patients with a different molecule of the same class demonstrated efficacy in preserving vestibular functions. SENS-218 is in late preclinical and a Phase II study could start as early as H2-2016. Our target price for Sensorion as of November 24th, 2015, is €10.03/share »

You can download the coverage initiation report at the following link:

November 16th, 2015: Aurgalys releases new analyst reports on Onxeo [Euronext:ONXEO]

novembre 25, 2015

Paris-Evry, France, November 16th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued new analyst report on Onxeo.

« Onxeo announced the Phase I Beleodaq + CHOP (BelCHOP) results for 1st line treatment of Peripheral T-Cell Lymphoma (PTCL). This trial was intended to determine the maximum tolerated dose of Beleodaq in combination with CHOP for a confirmatory Phase III study. The results confirmed the good tolerance profile of Beleodaq when combined with chemotherapy, at the approved dose of Beleodaq. Interestingly, the BelCHOP therapy also showed promising clinical activity with a Complete Response Rate of 72%, supporting further clinical investigation in the upcoming Phase III study (H1-2016) […] »

You can download our report (in English) at the following link:

November 12th, 2015: Aurgalys releases an analyst report on OSE Pharma [Euronext:OSE]

novembre 12, 2015

Paris-Evry, France, November 12th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on OSE Pharma

« With the authorization from 7 European countries, OSE Pharma is now ready to begin the Phase III trial in NSCLC for its lead drug candidate Tedopi. This drug candidate is an immunotherapy against cancer that has already demonstrated efficacy in phase II. Tedopi’s Phase III results are expected in 2018. »

You can download analyst report (in English) on the following link:

 

September 11th, 2015: Aurgalys releases an analyst report on Diaxonhit [Alternext:ALEHT]

septembre 11, 2015

Paris-Evry, France, September 11th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Diaxonhit

« Since 2014, Diaxonhit has been participating in the HIV consortium PROTHEVIH, which aims at developing innovative drugs and diagnostic tests to improve the management of HIV patients. After project leader Innavirvax published promising results on the VAC-3S therapeutic vaccine, Diaxonhit announced it will have a first prototype of an HIV prognosis test in H1-2016 (DIAG-3S). The company needs to demonstrate that the naturally-secreted antibodies against the 3S peptide (highly conserved on the HIV virus) can be used as an early marker of prognosis in HIV-infected patients. After validating the test, Diaxonhit could market DIAG-3S as early as 2018. Following this announcement, we adjusted our target price to €1.62/share. »

You can download analyst report (in English) on the following link:

Sep. 10th, 2015: Aurgalys initiates coverage on Biocorp Production [Alternext: ALCOR]

septembre 10, 2015

Paris- Evry, France, Sep. 9th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on Biocorp Production.

« Founded by Jacques Gardette in 2004, Biocorp has since built a strong experience in the development, production and marketing of medical devices for the pharmaceutical industry. The company developed innovative solutions for drug packaging and secured syringes. Biocorp signed two contracts for these products with Japanese Nipro and Italian Ompi, that could bring almost €20M in revenues by 2018. The company has also dedicated a significant portion of its R&D effort in the development of connected medical devices. The most advanced product is the Datapen (insulin pen) which is an injection device connected to a mobile application, allowing the user to record the dose of insulin injected, as well as the blood glucose level. The Datapen was developed to improve diabetic patients’ adherence to their treatment. Our target price for Biocorp as of September 9th, 2015, is €17.59/share. »

You can download the coverage initiation report at the following link:

Sep. 1st, 2015: Aurgalys initiates coverage on Abivax [Euronext: ABVX]

septembre 01, 2015

Paris- Evry, France, Sep. 1st, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on Abivax.

« Abivax is a biopharmaceutical company, specializing in the development of antiviral drugs and vaccines against infectious diseases. Its lead products include ABX203, for chronic hepatitis B management (currently in Phase II/III) and ABX464, for HIV patients (Phase IIa). Abivax has built strong partnerships with research institutions such as the CIGB in Cuba (ABX203), the Scripps Institute, French CNRS etc. Abivax also secured an agreement with the Finlay Institute in Cuba for marketing three prophylactic vaccines (typhoid fever, meningitis B/C and leptospirosis) in selected territories in Asia, Africa and South America. Our target price for Abivax as of August 31st, 2015, is €26.60/share. »

You can download the coverage initiation report at the following link:

August 24th, 2015: Performance of French Life Sciences and Healthcare Smallcaps, Aurgalys celebrates 2-year anniversary of Alys Indices!

août 24, 2015

Paris-Evry, France, August 24th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued its monthly publication of its indices measuring the performance of French, Life Sciences and Healthcare smallcaps.

Alys indices, measuring the performance of French biotech/ medtech smallcaps, were created 2 years ago. Since their inception (July 18th, 2013), the number of French smallcaps has increased from 37 to 63, and the total market capitalization has tripled (from €3.97B to €11.85B).

You can download our report on the following link:

 

July 8th, 2015: Aurgalys releases an Analyst Report on Quantum Genomics [Alternext:ALQGC]

juillet 15, 2015

Paris-Evry, France, July  8th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Quantum Genomics

« Quantum Genomics, developing cutting-edge drugs addressing unmet medical needs in the field of cardiovascular diseases, announced it would accelerate the clinical development of QGC101 in Congestive Heart Failure (CHF). Originally planned in 2017, the phase 2a clinical study has now been scheduled to begin in mid- 2016. […] »

You can download our note (in English) at the following link:

July 3rd, 2015: Performance of French Life Sciences and Healthcare Smallcaps, the IPO rally continues

juillet 03, 2015

Paris-Evry, France, July 3rd, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued its monthly publication of its indices measuring the performance of French, Life Sciences and Healthcare smallcaps.

59 companies in the Alys France index with the inclusion of newly-listed Abivax and Amplitude Surgical. There are 4 more companies in the process of going public with Amoeba, Biocorp, Biophytis and Cellnovo. June was characterized by highly volatile markets and Alys France lost 6.9% this month. The strongest performer of the month was Oncodesign (+153%).

You can download our report on the following link:

 

 

June 24th, 2015: Aurgalys initiates coverage on OSE Pharma [Euronext: OSE]

juin 24, 2015

Paris- Evry, France, June 24th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on OSE Pharma.

« OSE Pharma is a company specializing in cancer immunotherapy. Their lead product, Tedopi, offers new perspectives in lung cancer management, particularly in Non-Small Cell Lung Cancer (NSCLC) that is resistant to chemotherapy and has a poor prognosis. Efficacy of Tedopi has already been demonstrated in a Phase II study, and the product is now ready to enter Phase III clinical studies in Q4- 2015. »

You can download the coverage initiation report at the following link:

June 9th, 2015: Aurgalys releases new analyst reports on Onxeo [Euronext:ONXEO]

juin 09, 2015

Paris-Evry, France, June 9th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued new analyst report on Onxeo.

« Onxeo released the final results of Validive’s Phase II clinical trial, which confirmed the preliminary findings published last October. Taken daily over the course of the chemoradiotherapy treatment (8 weeks), Validive (clonidine Lauriad) was able to reduce the occurrence of Severe Oral Mucositis, while reducing chemoradiotherapy-related adverse events (nausea, dysphagia). This proof of concept establishes the basis of the Phase III study, expected to start at the end of 2015 […] »

You can download our report (in English) at the following link:

June 8th, 2015: Performance of French Life Sciences and Healthcare Smallcaps: total market capitalization of €10.2B

juin 08, 2015

Paris-Evry, France, June 8th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued its monthly publication of its indices measuring the performance of French, Life Sciences and Healthcare smallcaps.

With a 6.4% increase in May 2015, the French Biotech/Medtech Smallcaps reached a total market capitalization of €10.2 B. Out of the 57 companies included in the Alys France index, 27 are listed in Alternext Paris. As a comparison, Alternext alone weighs €10 B. Again, the Alys Therapeutics showed the strongest performance with a 10.1% increase. This is mainly explained by Cellectis’s 37.1% increase in May, following rumors of a potential acquisition by Pfizer.

You can download our report on the following link:

June 4th, 2015: Aurgalys releases an analyst report on Diaxonhit [Alternext:ALEHT]

juin 04, 2015

Paris-Evry, France, June 4th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Diaxonhit

« Diaxonhit reported positive results from the CARGO II clinical study for Allomap, a blood test used for heart transplant rejection monitoring. The study, conducted on European patients, demonstrated similar results obtained in the previous CARGO I study, performed in the US. Last April, during a symposium organized by CareDx and Diaxonhit, interesting data were presented regarding new opportunities for extended use of the Allomap test: a correlation between the Allomap score and patient long-term survival could validate its use as a prognosis test; Allomap combination with a donor-derived cell-free DNA test could improve its performance. Diaxonhit also recently announced the licensing of therapeutic assets to Felicitex Therapeutics that could represent significant upside through upfront and milestones payments, as well as royalties on sales, should the products reach the market. We maintain our valuation of Diaxonhit at €105.2M (Enterprise value). This represents a value of €1.64 per share including estimated net cash of €10.6M. »

You can download analyst report (in English) on the following link:

May 18th, 2015: Aurgalys initiates OSE Pharma analyst coverage and assists the company with its investor relations

mai 20, 2015

Paris-Evry, France, May 18th, 2015 – Aurgalys announces that we have been chosen by OSE Pharma to initiate coverage of their company, listed on Euronext Paris (OSE). Aurgalys will also manage OSE Pharma’s investor relations.

OSE Pharma is a French biopharma company, recently listed on Euronext Paris (March 30th, 2015), which develops immunotherapy products against invasive/metastatic late-stage cancers. Its Memopi® technology triggers the immune system to eliminate cancer cells. OSE Pharma’s lead product, Tedopi®, is a patented combination of 10 peptides selected and optimized from 5 tumor antigens, often present in invasive late-stage cancers. Tedopi® has been successfully tested in a phase 2 study in patients with non-small cell lung cancer (NSCLC), and a phase 3 study should be launched during the second half of 2015.

Aurgalys is planning to publish the first analysis of OSE Pharma by mid-June 2015. This study will address the potential and the valuation of the company, and would be available to all the financial community.

In addition, we are going to set up regular meetings allowing the financial community to directly meet the management of OSE Pharma and discuss their strategy, projects, and future milestones of the company.

“With almost 20 IPOs in the life sciences and healthcare sector since 2014, structuring a company’s investor relations is essential to create and maintain interest within the financial community. OSE Pharma’s decision to choose our services is evidence of our expertise in building an ongoing liaison between existing or prospective shareholders, and issuers” says Dr Mickael Dubourd, Head of Investor Relations/ Equity Research at Aurgalys.

You can download our press releases in English and French on the following links:

May 7th, 2015: Performance of French Life Sciences and Healthcare Smallcaps: 2 new IPOs on Alternext Paris

mai 07, 2015

Paris-Evry, France, May 7th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued its monthly publication of its indices measuring the performance of French, Life Sciences and Healthcare smallcaps.

Innate Pharma is the featured Biotech of the month, thanks to its $1.3 B deal with AstraZeneca to develop IPH2201 in the immuno-oncology field. The company almost doubled its market capitalization reaching €832 M as of April 30th, 2015. Also, the Alys France index welcomes two new biotech companies: Plant Advanced Technologies, producing active ingredients from plants, and Sensorion, specialized in inner ear disorders. The Alys France index gained 6.8% in April.

You can download our report on the following link:

 

March 25th, 2015: Aurgalys releases new analyst reports on Onxeo [Euronext:ONXEO]

mars 25, 2015

Paris-Evry, France, March 25th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued new analyst report on Onxeo.

« Onxeo’s 2014 annual results confirmed the successful integration of Danish Topotarget and the relevance of this strategic acquisition in the field of orphan oncology. The merger allowed the company to generate more than €35M in revenue for 2014 (pro forma), and a net profit of €7.3M if non-recurring expenses are excluded. […] »

You can download our report (in English) at the following link: